TRT Cardiovascular Risk — Guidelines vs. Evidence
How major society guidance on testosterone therapy cardiovascular safety compares to the landmark trial evidence RAGMD has indexed.
Review date on record: Nov 2026. Named clinician approval is not independently verified on this page.
RAGMD evidence position
Testosterone replacement therapy does not significantly increase major adverse cardiovascular events in hypogonadal men with elevated cardiovascular risk.
Guideline vs. evidence
| Guideline | Society position | RAGMD evidence |
|---|---|---|
| Endocrine Society (2018) | Recommends against TRT in men with uncontrolled heart failure or recent MI/stroke; emphasizes individualized risk-benefit assessment. | TRAVERSE (N=5,246) found noninferior MACE rates vs. placebo in hypogonadal men with CVD or high risk — the largest RCT directly addresses this question.Open evidence analysis → |
| AHA / ACC (general CVD prevention) | Focuses on lifestyle and established CV risk factors; does not provide specific TRT cardiovascular outcome guidance. | RAGMD synthesizes TRAVERSE and observational cohorts (Vigen, Baillargeon) — observational harm signals conflict with RCT data due to confounding.Open evidence analysis → |
| FDA labeling | Requires testosterone products to carry cardiovascular risk language based on historical observational signals. | Post-TRAVERSE, the evidence base is anchored on RCT noninferiority; labeling reflects precautionary stance rather than trial-confirmed harm.Open evidence analysis → |
Key studies
- TRAVERSE primary MACE outcome · PMID 37326322
- Vigen observational cohort (conflicting) · PMID 24193080